Generex Biotechnology (GNBT)

Treating diabetics with an insulin that is sprayed in the mouth and absorbed by the inner lining of your cheeks is pain free unlike injections. Only a diabetic knows how painful, inconventient, and embarrassing giving yourself injections can be when you are in public or travelling. Oral-lyn made by Generex (GNBT) offers the diabetic an insulin spray packaged in a container that looks like an inhaler and requires no refrigeration. One spray equals one unit of insulin. It is as simple as that. Spray the required dose in your mouth prior to a meal and off you go. No fuss, no embarrassment. This product is now available in South America and India. It should be availabe in the U.S. market in less that two years. Want a no brainer investment? Put your money in GNBT.

Delivery of insulin through the mouth vs the lungs was the major debate. Generex took the oral route and others took the lung approach. Lung approach was a failure. The lung method led to selling on Generex becuase investors concluded that the inhaler and "bucal" delivery were the same. The opposite should have taken place--the competition was repudiated. There have been no known repudiations of the Generex approach making there market more unchallenged than ever. GNBT continues to gain goverenment approvals to sell globally. The rejection in 08 and general market pressues have discounted this stock to "steal levels".

Insulin is just the begining. Other medicines can be delivered using this method and Generex owns the patents to the delivery mechanism. This makes them a great acquisition target by a major pharma as well as being a great growth play. Wish I had more cash.